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Micelles derivatized with octreotide
as potential target-selective contrast
agents in MRI‡§
Anna Morisco,a Antonella Accardo,a Eliana Gianolio,b Diego Tesauro,a
Ettore Benedettia and Giancarlo Morellia∗
New amphiphilic monomers (OCA-DTPAGlu and OCA-DOTA) containing, in the same molecule, three different functions:
(i) the chelating agent (DTPAGlu or DOTA) able to coordinate gadolinium ion, (ii) the octreotide bioactive peptide able to
target somatostatin receptors, and (iii) a hydrophobic moiety with two 18-carbon atoms alkyl chains have been designed and
synthesized by solid-phase methods. The novel amphiphilic monomers aggregate, in water solution, giving stable micelles
at very low concentration (cmc values of 2.3 × 10−6 mol kg−1 and 2.5 × 10−6 mol kg−1 for OCA-DTPAGlu and OCA-DOTA,
respectively) as confirmed by fluorescence spectroscopy. Fluorescence studies and circular dichroism experiments indicate,
for the two compounds as well as for their gadolinium complexes (OCA-DOTA(Gd) and OCA-DTPAGlu(Gd)), the complete
exposure of octreotide on the micelle surface, and the predominant presence of an antiparallel β-sheet peptide conformation
characterized by a β-like turn. The high relaxivity value (r1p = 13.9 mM−1 s−1 at 20 MHz and 25 ◦C), measured for micelles
obtained by the gadolinium complex OCA-DTPAGlu(Gd), indicates these aggregates as promising target-selective magnetic
resonance imaging (MRI) contrast agents. Copyright c© 2008 European Peptide Society and John Wiley & Sons, Ltd.
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Introduction
Somatostatin (SST) is a neuropeptide with a wide role in the
physiological control and pharmacological action as inhibitor
of growth hormone, insulin and glucagon secretion; its effect
is mediated via five G protein coupled membrane receptors
(SSTR1-5) [1]. The five SST receptors, especially SSTR2, are widely
overexpressed in homogenous and heterogeneous manner in
tumor tissues such as gastroenteropancreatic neuroendocrine
tumors, gliomas, meningiomas and breast tumors [2–4]. This
is a challenging issue in oncology allowing the use of reg-
ulatory SST peptide to recognize receptors overexpressed in
tumor cells. Unfortunately, SST half-life in plasma is extremely
short [5] and the availability of synthetic analogs became an
absolute necessity for any progress in this field. Many efforts
were dedicated to synthesize a large variety of analogs and to
select low molecular weight peptides stable in vivo and able
to recognize most of the SSTRs. This research led to a cyclic
eight-amino acid peptide (octreotide) (Sandostatin) [6] (Figure 1)
able to bind to the most frequently overexpressed SSTR2 and
to a lesser extent to SSTR5 [7]. For the presence of unnat-
ural D aminoacid residues and the alcoholic C-terminus, this
peptide is highly resistant to enzymatic degradation and is
able to restore the β-turn conformation unavoidable to inter-
act with the receptors [8]. In light of these properties and of
nontoxic side effects, octreotide is clearly a useful tool in the
cancer management and more than 10 years ago was intro-
duced in clinical practice to limit tumor growth [9]. Several
preclinical studies strongly support the concept that binding
of octreotide to SSTR is followed by rapid internalization of
the receptor–ligand complex [10]. The mechanism of endocy-
tosis is exploited to transport in the cell octreotide-conjugates
containing therapeutics and diagnostics, such as the spindle poi-
son taxol [11], and PNA sequences as antisense therapeutics
[12]. Moreover, for diagnostic use, several octreotide derivatives,
modified on the N-terminal moiety with a bifunctional chelator
suitable for labeling radiometals such as 99mTc, 111In, 67/68Ga,
have been designed, synthesized, and used as in vivo contrast
agents in nuclear medicine techniques positron (emission tomog-
raphy (PET) and single photon emission computed tomography
(SPECT)) [13–16].
These results suggest theapplicationofoctreotideas thevehicle
of contrast agents in magnetic resonance imaging (MRI). MRI is
one of the most efficient in vivo imaging techniques, giving very
resolved images with anatomical information. In these diagnostic
procedures, the images are obtained by accumulating contrast
agents. In SPECTorPET, the request concentrationof radionuclides
in the cancer tissues is 10−10 M, while MRI technique, due to its
lower sensitivity, needs high concentration (at least 10−4 M) of
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Figure 1. Amino acid sequence and structure of octreotide peptide
(Sandostatin).
paramagnetic gadolinium complexes. This critical point can be
overtaken by accumulating high concentration of contrast media
in the site of interest. The use of a peptide probe based on only
one unit of gadolinium complex for a peptide molecule could
not overcome the problemof concentration of the contrast agent:
mostof tumor cells overexpresson theirmembraneapproximately
some million of SSTRs leading a number of contrast agents too
low in the cells.
To increase thenumberof contrastagentson the targetcells, the
bindingof a largenumberof gadoliniumcomplexes to thepeptide
probe is required. During last years, supramolecular aggregates,
such as micelles [17], vesicles and liposomes [18], all containing a
highnumber of stableGd(III) complexeswereprepared.Moreover,
supramolecular aggregates derivatized on their external surface
with bioactive molecules (peptides or antibodies) have been
proposed as target-selective contrast agents inMRI [19]. Following
this strategy, we developed several supramolecular aggregates by
assembling together two amphiphilic monomers, one containing
a gadolinium complex and the other the CCK8 octapeptide able
to recognize cholecistokinin receptors overexpressed in human
tumor cells [20,21].
More recently we reported the synthesis, the aggregation
behavior, the structural characterization and the relaxomet-
ric properties of a monomer with an ‘upsilon’ shape (MonY)
[22]. The core of this molecule is a lysine residue in which
the three reactive functions are derivatized with: the chelating
agent N,N-bis[2-[bis(carboxy-ethyl)amino]ethyl]-L-glutamic acid
(DTPAGlu), a DTPA derivative able to give very stable Gd(III)
complex; the bioactive C-terminal octapeptide sequence of the
cholecystokinin hormone (CCK8); and a hydrophobic moiety
containing two alkyl chains with 18 carbon atoms each. In
this paper we report, the synthesis in solid phase, the ag-
gregation properties and the relaxometric behavior of two
novel octreotride-conjugate amphiphiles (OCA: OCA-DOTA and
OCA-DTPAGlu) in which the hydrophobic moiety is formed
by two hydrocarbon tails at 18 carbon atoms each, while
the hydrophilic head group still contains the DTPAGlu or
tetraazacyclododecane-tetraacetic acid (DOTA) chelating agents
or their gadolinium complexes, and the octreotide bioactive pep-
tide (Figure 2).
Results and Discussion
Monomers Design and Synthesis
The monomers design has to fulfil two requirements: (i) chemical
modifications on octreotide should preserve the peptide receptor
binding capability; (ii) after the aggregation process, the peptide
molecules and thegadoliniumcomplexeshave to lie inhydrophilic
shell of the supramolecular aggregates to preserve the peptide
bioactivity and to allow water exchange in the gadolinium coor-
dination sphere. The first requirement was fulfilled by introducing
modifications at N-terminal end of the peptide sequence. In fact,
recent studies show that a hydrophilic or hydrophobic chain cova-
lentlyboundontheN-terminusofDPheresidueresults in loweffect
on binding constants of octreotide to the receptors [23]. The sec-
ond need could be satisfied by introducing two units of 21-amino-
4,7,10,13,16,19-hexaoxaheneicosanoic acid (AhOH) between the
lysine residue and the octreotide N-terminal residue. The AhOH
linkerwaschosento increasethehydrophilicityof theheadwithout
change the charge of the monomers. Moreover, the oxoethylene
moieties are not toxic, are able to reduce aggregate clearance
through the reticulo-endothelial system (RES) [24] and they avoid
adsorption of blood proteins into the supramolecular aggregates.
The length of linkers was selected, according to the biological
results previously obtained on similar aggregates derivatized with
CCK8 or 7-14-bombesin, in order to favor a good exposure of
octreotide on the external aggregate surface. The branching of
the monomers headgroup was achieved using a lysine residue.
On its α amine function, another unit of the linker was bound to
space the hydrophilic head from the lipophilic tails; while on lysine
side chain, the selected DOTA or DTPAGlu chelating agents were
condensed to distance them far away from the octreotide moiety.
DOTAbelongs to themacrocycle class of chelating agentswhile
DPTAGlu is a branched chelating agent. Both ligands are able
to coordinate Gd(III) ions with high-stability constants saturating
eight coordination positions, thus leaving the last position for
water coordination and allowing water exchange in gadolinium
coordination sphere. They were selected to study the influence
of the steric hindrance and of the residual charge present in the
hydrophilic shell on the aggregation behavior.
The chemical synthesis of the two monomers, OCA-DOTA and
OCA-DTPAGlu, was fully performed on solid support according
to standard SPPS protocols following the Fmoc/tBu chemistry
[25]. The synthetic scheme is reported in detail in Figure 3. The
preloaded H-Thr(tBu)-ol-(2-chrolo-trityl) polymeric resin was used
to obtain the alcoholic function on the C-terminus. The asym-
metric compounds were obtained by the introduction of a lysine
residue, orthogonally protected by Dde and Fmoc on the α and
ε amine functions, respectively. The Dde protecting group was
preferred to Mtt protecting group to avoid a partial cleavage
from the resin in acid-labile removal conditions and because of its
stability during the Fmoc removal by treatment with piperidine.
After removal of Fmoc, DTPAGlu-pentaester or DOTA-triester,
activated by HATU, were condensed on lysine side chain. The Dde
removalwasobtainedbybrief treatmentwith2%hydrazine inN,N-
dimethylformamide,givingtheα freeaminefunction,onwhichthe
AhOH linker andN,N-dioctadecylsuccinamic acidwere condensed.
At the end of the monomers assembly, acetamidomethyl (Acm)
removal from the cysteine residues and disulfide bridge formation
were achieved by Tl(CF3CO2)3 treatment on a solid support.
Cleavage was performed using standard trifluoroacetic acid
(TFA)/tri-isopropylsilane (TIS)/H2O mixtures, to allow complete
removal of protecting groups from all the amino acid side chains
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Figure 2. Schematic representation of the two octreotide conjugate amphiphiles: (C18)2-(AhOH)-Lys(DTPAGlu)-(AhOH)2-octreotide, OCA-DTPAGlu, and
(C18)2-(AhOH)-Lys(DOTA)-(AhOH)2-octreotide, OCA-DOTA.
and from chelating agents carboxylic groups. The crude products
were purified by preparative reversed-phase HPLC to a final
purity of 90% and isolated in 30–40% yields in lyophilized form.
Their molecular masses were determined by MALDI-TOF mass
spectroscopy.
The OCA-DOTA(Gd) and OCA-DTPAGlu(Gd) gadolinium com-
plexes were obtained by adding increasing amounts of a con-
centrated GdCl3 solution to the free base monomers at neutral
pH and at room temperature. To avoid the relaxivity contribution
of free gadolinium, the excess of ions was removed at pH 10
as insoluble hydroxide as already reported for other DTPAGlu or
DOTA gadolinium complexes. The Gd(III) titration is conveniently
followed by measuring 1H-relaxation rates.
Aggregates Preparation and Characterization
Supramolecular aggregates have been prepared by dissolving
OCA-DOTA and OCA-DTPAGlu free base or their corresponding
gadolinium complexes (OCA-DOTA(Gd) and OCA-DTPAGlu(Gd)),
in phosphate buffer at pH 7.4 following well-assessed procedures.
On the basis of structural characterizations performed on
self-assembling aggregates of a similar branched amphiphilic
compound containing the CCK8 peptide and the DTPAGlu
chelating agent, small micelles are expected for OCA-DOTA,
OCA-DTPAGlu and their gadolinium complexes, in water solution
[22]. Anyway, the self assembling of the amphiphilic compounds
occurs only over a critical micellar concentration (cmc) that can
be measured by a fluorescence based method using 8-anilino-1-
napthalene sulfonic acid ammonium salt (ANS) as a probe. This
aromatic organic molecule is fluorescence sensitive according
to the environment polarity: it is essentially nonfluorescent in
water, but highly fluorescent in nonpolar environments such
as the inner micellar compartment [26]. The wavelength of
maximum fluorescence intensity varies with the environment,
and usually occurs between 450 and 480 nm. The addition of
the amphiphilic surfactant to the aqueous ANS solution causes
an increase in the fluorescence intensity which reaches a plateau
at higher concentrations, when all the dye is entrapped in the
micellar hydrophobic compartment. The experimental measure
of the ANS fluorescence intensity at 480 nm, corresponding
to the maximum of spectrum, on function of OCA-DOTA or
OCA-DTPAGlu concentration (Figure 4(a)), provides the cmc
values. The break points in Figure 4(a) indicate cmc values of
2.3 × 10−6 mol kg−1 and 2.5 × 10−6 mol kg−1 for OCA-DTPAGlu
and OCA-DOTA, respectively, thus confirming the expected high
stability of the resulting supramolecular aggregates. The same
experiments produce the plot reported in Figure 4(b) for the
corresponding gadolinium complexes OCA-DTPAGlu(Gd) and
OCA-DOTA(Gd). The first monomer aggregates at concentrations
higher than 2.0 × 10−5 mol kg−1, while the second one does
not give supramolecular structures at concentrations lower than
2.6 × 10−4 mol kg−1, as clearly indicated by the fluorescence
experiment. In fact, ANS probe remains not fluorescent during
the titration with the amphiphilic molecule, thus indicating that
an aggregation process occurs. The different behavior between
the two monomers could be explained as a function of the
different number of negative charges preserved on the head
group after the gadolinium complexation: OCA-DTPAGlu(Gd)
monomer retains two negative charges, while OCA-DOTA has
no charges. The complete loss of charges on the Gd-DOTA
gadolinium complex produces a remarkable reduction of the
anionic character of the amphiphilic monomer which is unable to
aggregate [27].
www.interscience.com/journal/psc Copyright c© 2008 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2009; 15: 242–250
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Figure 3. Scheme of the chemical procedures for the solid-phase synthesis of the two monomers OCA-DTPAGlu and OCA-DOTA. Resin is schematically
represented as a broken curve.
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Figure 4. Fluorescence intensity of ANS fluorophore at 480 nm versus: (a) OCA-DTPAGlu and OCA-DOTA concentration; (b) OCA-DTPAGlu(Gd) and
OCA-DOTA(Gd) concentration. The cmc values are established from graphical break points.
Physicochemical Studies on the Octreotide Moiety
Biological data concerning SST analogs obtained by introducing
covalent conformational constraints, suggested that -Phe-D-Trp-
Lys-Thr-aminoacidic sequencecontainsall theelementsnecessary
for the expression of the SST biological activities versus SSTR2
[7]. Literature NMR studies indicated that octreotide adopts a
predominant antiparallel β-sheet conformation characterized by
a type II′ β-like turn across residues D-Trp4 and Lys5 [28], and
these results were also confirmed by X ray structural studies
[29]. Therefore, all octreotide conjugates should preserve this
conformation and chemical alterations should not affect the
D-Trp residue. Fluorescence experiments and CD studies were
J. Pept. Sci. 2009; 15: 242–250 Copyright c© 2008 European Peptide Society and John Wiley & Sons, Ltd. www.interscience.com/journal/psc
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carried out to prove that the peptide moiety in the amphiphilic
molecules keeps the conformational requirements unaltered also
after micelles formation and that it remains well exposed on
the micelle surface. The exposure of the bioactive portion of the
monomers on aggregates surface was assessed bymonitoring the
fluorescence emission due to the indole moiety of the tryptophan
residue.Usually, thisfluorophore showsanemissionpeakcentered
at 350 nm in polar solvents while in hydrophobic solvents the
maximum shifts occurs at 330 nm [30]. The fluorescence emission
spectra of the three aggregates (Figure 5) were recorded at 25 ◦C
and at monomer concentration (1.0 × 10−5 M for OCA-DOTA and
OCA-DTPAGlu; 1.0 × 10−4 for OCA-DTPAGlu(Gd)), higher than
cmc to be sure of the presence of aggregates in solution. The
fluorescence maximum at 350 nm suggests for OCA-DOTA, a
complete exposure of D-Trp residue in the hydrophilic external
space. In the case of OCA-DTPAGlu and OCA-DTPAGlu(Gd), the
maximum is centered at 346 nm, this value, slightly shifted with
respect to 350 nm, indicates that most of the indole groups on
tryptophan side-chain lies in the hydrophilic environment. The
slight difference between OCA-DOTA and OCA-DTPAGlu could be
attribute to the different steric hindrance of the chelating agents
which can drive the micelle structure. Instead, the octreotide
disposition seems not to be affected by gadolinium coordination,
reducing the negative charge on the hydrophilic surface. This
result suggests the use of the octreotidepeptide todrive the entire
aggregate toward SST receptors present on cell membranes.
The effects on the conformational structure of the octreotide
peptide in the two amphiphilic molecules were assayed by CD
measurements. Figure 6(a) shows the CD spectra of OCA-DOTA
and OCA-DTPAGlu at 1.0 × 10−4 M concentration, above their
cmc values. The octreotide wild-type spectrum was also reported
for comparison. All spectra indicate predominant presence of
an antiparallel β-sheet conformation characterized by a β-like
turn, clearly suggesting that the disulphide bridge is conserved
on the aggregates surface. OCA-DTPAGlu and octreotide spectra
are nearly superimposable in the 190–260 nm range. Instead,
the OCA-DOTA spectrum in 190–210 nm range shows a blue
shift of the minimum, which may indicate some conformational
modifications, but widely confirms the β-sheet conformation.
Moreover, OCA-DTPAGlu spectra at three different concent-
rations are also reported in Figure 6(b). The presence of oxoethy-
lenic linkers and lipophilic tails on peptide N-terminus could
induce some changes in peptide conformation. By decreasing
concentration below the cmc, even if some spectral modifications
are observed, the β-sheet rearrangement is preserved. This
variation disappears when the monomer self-aggregates in
solution above cmc. The steric hindrance on micelles surface
might reduce the degree of freedom and restore the minimum
octreotide conformation.
Relaxivity Measurements
The parameter for an evaluation of an MRI contrast agent is
its relaxivity, i.e. the potency to shorten the relaxation times of
the solvent water protons. The measured relaxivity value (r1p) is
defined as the paramagnetic contribution to themeasured proton
longitudinal relaxation rate (R1obs) of a solution containing 1.0 mM
concentration of gadolinium according to Eqn (1) [31]
R1obs = [Gd] · r1p + R1W (1)
whereR1w is thediamagnetic contributionofpurewater (0.38 s−1).
The relaxivity of OCA-DTPAGlu(Gd), was measured at monomer
concentration higher than the calculated cmc to be sure that
the molecules are aggregated in the micellar form. A value
of 13.9 mM−1 s−1 has been determined at 20 MHz and 25 ◦C
(Figure 7). This value was then confirmed mineralizing, with HCl
37% at 120 ◦C overnight, a given quantity of sample solution to
determinetheexactconcentrationofGd(III)present in thesolution:
from the measure of the observed relaxation rate (R1obs) of the
acidic solution, knowing the relaxivity (r1p) of Gd(III) aquoion in
acidic conditions (13.5 mM−1 s−1), it was possible to calculate the
exact Gd(III) concentration (Eqn (1)) (This method was calibrated
using standard inductively coupledplasma (ICP) solutions, and the
accuracy was determined to be 1%). At this point, knowing [GdL]
and measuring R1obs of the micellar mother solution, the same
Eqn (1)wasused tocalculate themicellar relaxivity. Relaxivityvalue
ofOCA-DTPAGlu(Gd)micelles (13.9 mM−1 s−1) is in the same range
of the value previously reported (15.0 mM−1 s−1) for aggregates
obtained by self assembling of a similar monomer containing
the CCK8 peptide (MonY-Gd) [22]. The slight difference could be
probably ascribed to different aggregation number or size.
The analysis of nuclear magnetic relaxation dispersion (NMRD)
profile of the lipophilic aggregated system has been made ac-
cording to the Solomon–Bloembergen–Morganmodel, modified
Figure 5. Fluorescence spectrum of tryptophan residue of: (a) OCA-DTPAGlu and OCA-DOTA aggregates; (b) OCA-DTPAGlu(Gd) aggregate. Fluorescence
spectra were excited at 280 nm.
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Figure 6. Circular dichroism profiles of: (a) octreotide, OCA-DTPAGlu and OCA-DOTA (b) of octreotide and OCA-DTPAGlu at 1.0 × 10−4 M, 1.0 × 10−5 M,
1.0 × 10−6 M concentrations.
Figure 7. 1/T1 NMRD profile of OCA-DTPAGlu(Gd) at pH 7.4 and 25 ◦C,
normalized to 1 mM Gd (III) ion. This figure is available in colour online at
www.interscience.wiley.com/journal/jpepsci.
according to the Lipari-Szabo approach [32–34] to obtain an accu-
rate determination of the reorientational correlation time (τR), that
is strictly related to the molecular size of the investigated system.
This model is generally applied to the systems with a faster local
motion (governed by τl) and a slower global motion (governed by
τg); the extent of local to global contribution to the overall motion
is determined by an order parameter (S2) that can vary from 0 to 1.
The experimental data τl = 250 ps, τg = 2900 ps and S = 0.3
were fitted by considering one water molecule in the inner
coordination sphere for each Gd(III) complex (nw = 1) and fixing
the exchange lifetime of the coordinated water molecule (τM) to
the (60 ns) previously determined for the similar micellar system
containing the CCK8-peptide functionalizedmonomer (MonY-Gd)
[22] because of the low solubility of OCA-DTPAGlu(Gd) system,
which prevents any direct 17O-NMR R2p versus T measurement.
In Vitro Biological Assays
Receptor binding ability of OCA-DTPAGlu in micellar form has
been evaluated by standard nuclear medicine experiments.
Radiolabeling of the aggregates was performed at concentrations
above critical micellar concentration to avoid the presence of free
monomers in solution. Trace amounts of 111InCl3 andup to500 µCi
wereaddedto theaggregate formulationafteradditionofanequal
volume of 0.5 N sodium citrate. Confirmation of incorporation of
the radioactive label into the aggregates was obtained by gel
filtration. 111In-labeled aggregates showed preferential binding to
A431 cells overexpressing the sstr2 by transfection compared to
control cells; in fact 3.8%of boundplus internalized radioactivity in
receptor expressing cell against 1.6% for control cellswasobtained
in a preliminary experiment performed at 37 ◦C.
Conclusions
New amphiphilic monomers (OCA-DTPAGlu and OCA-DOTA)
containing, in the same molecule, three different functions:
(i) the chelating agent (DTPAGlu or DOTA) able to coordinate
gadolinium ion, (ii) the octreotide bioactive peptide able to target
SSTR2 and SSTR5 SST receptors and (iii) a hydrophobic moiety
with two 18-carbon atoms alkyl chains, have been designed and
synthesized by solid-phase methods. In water solution at pH 7.4,
the peptide-conjugate amphiphiles self-assemble as micelles at
low concentration as confirmed by fluorescence measurements,
using the fluorescent ANS probe. The corresponding gadolinium
complexes present a different aggregation behavior: While OCA-
DTPAGlu(Gd) gives stable micelles, OCA-DOTA(Gd), which does
not contain charges on the hydrophilic head, remains in the
nonaggregated state in the explored concentration range. As
consequence of this aggregation behavior, OCA-DTPAGlu(Gd)
seems a very promising target-selective MRI contrast agent.
It presents the high relaxivity value expected for amphiphilic
gadolinium complexes in aggregated form; a high stability
of the micelles, and above all the exposure of the bioactive
octreotide peptide on the micelle external surface, in the correct
conformation to bind the target receptors. The selective binding
of OCA-DTPAGlu in micellar formwas determined in a preliminary
experiment, in which the octreotide derivative, at concentration
higher than its cmc, is labeled with 111In. 111In-labeled aggregates
show preferential binding to A431 cells overexpressing SSTR2
compared to control cells (3.8% against 1.6% of bound plus
internalized radioactivity). As already reported in the case of
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a similar compound containing the CCK8 peptide, MonY-Gd,
micelles of OCA-DTPAGlu(Gd) belongs to novel class of MRI
contrast agents. They could be able to target SSTR2 and SSTR5
receptors, well-assessed targets for several human tumors.
Experimental Methods
Materials and Methods
Protected Nα-Fmoc-amino acid derivatives, coupling reagents
and H-Thr(tBu)-ol-(2-chrolo-trityl)-resin were obtained from
Calbiochem-Novabiochem (Laufelfingen, Switzerland) and INBIOS
(Napoli, Italy). Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosa-
noic acid (Fmoc-AhOH-OH) was purchased from Neosys-
tem (Strasbourg, France). The 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetate terbutil ester [(DOTA(tBu)3] was purchased
fromMacrocycles (Richardson, Texas). DTPAGlu pentaester chelat-
ing agent (N2,N2-bis[2-[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-
amino]ethyl]-L-glutammic 1,1-dimethylethyl ester) and the N,N-
dioctadecylsuccinamic acid were synthesized according to the
experimental procedure reported in literature [35,36]. All other
chemicals were commercially available at Sigma-Aldrich (Milwau-
kee WI, USA) or Fluka (Buchs, Switzerland) and were used without
further purification. All solutions were prepared by weight using
doubly distilled water. The pH of all solutions was kept constant at
7.4 in phosphate buffer.
Synthesis of OCA-DOTA and OCA-DTPAGlu
Peptide synthesis was carried out in solid-phase under standard
conditions using Fmoc strategy, [25] on H-Thr(tBu)-ol-(2-chrolo-
trityl)-resin (0.70 mmol/g, 0.15 mmol scale, 0.214 g). The peptide
chain was built by sequential coupling and Fmoc deprotection of
the following sevenFmoc-aminoacidderivatives: Fmoc-Cys(Acm)-
OH, Fmoc-Thr(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-DTrp(Boc)-OH,
Fmoc-Phe-OH, Fmoc-Cys(Acm)-OH, Fmoc-DPhe-OH. All couplings
were performed twice for 60 min, by using an excess of four
equivalents for the single amino acid derivative. The carboxylic
functions of α-amino acids were activated in situ by the standard
1-hydroxybenzotriazole/benzotriazol-1-yl-oxy-tris-pyrrolidino-
phosphonium/N,N-diisopropylethylamine (HOBt/PyBop/DIPEA)
procedures in DMF. Fmoc deprotections were obtained by 30%
piperidine solution in DMF. The coupling steps were monitored
by the qualitative Kaiser test. When the peptide synthesis was
complete, the Fmoc N-terminal protecting group was removed
and two residues of Fmoc-AhOH-OH were condensed by using,
for each residue, an excess of two equivalents activating the
carboxylic function similarly in a single coupling for 60 min under
N2 flow at room temperature. After Fmoc removal from the
N-terminal end of the peptide derivative, 0,320 g (0.60 mmol) of
Dde-Lys(Fmoc)-OH, activatedbya stoichiometric amountofPyBop
and HOBt and two equivalents of DIPEA in DMF, were coupled by
stirring the slurry suspension of the resin for 60 min. The solution
was filtered and the resin was washed with three portions of DMF.
After removal of the Fmoc group on side chain of lysine residue,
the chelating agent (DTPAGlu pentaester or DOTA trisester)
was linked, through its free carboxyl function, to the ε-NH2 of
the lysine residue. This coupling step was performed using two
equivalents of the chelating agent, HATU and four equivalents of
DIPEA in DMF as a solvent. The coupling time, compared with the
classical solid-phase peptide synthesis protocol, was increased up
to 120 min. The resin was washed three times with DMF, then, the
1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)3-methylbutyl group
(Dde) was removed by treatment with DMF/Hydrazine mixture
(98 : 2). The peptide-resin was stirred with 3.0 ml of this solution
for 10 min. The treatment was repeated twice, and the reaction
was monitored by the qualitative Kaiser test. On N-terminal
moiety, the Fmoc-AhOH-OH linker was coupled following the
same procedure above described. After the removal of N-terminal
Fmoc protecting group, N,N-dioctadecylsuccinamic acid (0.187 g,
0.3 mmol) in DMF/DCM (1/1) mixture were condensed. The
coupling reaction was repeated twice under N2 flow for 60 min.
The lipophilic moiety was activated in situ by the standard
HOBt/PyBop/DIPEA procedure. The deprotection (Acm removal)
and the oxidation reaction of cysteine residues were carried out
at same time adding 1.2 eq Tl(CF3CO2)3 to a suspension of the
peptidyl resin in DMF/anisole (19 : 1) stirring the mixture for 18 h
at 0 ◦Cmonitoring at times by the colorimetric Ellmann test [37].
The peptide derivatives were cleaved from the solid support
by suspending the resin in 10 ml of TFA/TIS/H2O (95.5/2/2.5)
mixture for 120 min. During this step all the amino acid side
chains and the carboxylic groups of the chelating moiety were
simultaneously freed from their protecting groups. Free peptide
derivatives were precipitated in cold water and lyophilized from a
50%H2O/CH3CN solution. The crude compoundswere purified by
RP-HPLC. Preparative RP-HPLC was carried out on a Shimadzu 8A
(Kyoto, Japan) apparatus equipped with an UV Shimadzu detector
using a Phenomenex (Torrance, CA) C4 column, 22 mm× 250 mm
with a flow rate of 20 mlmin−1. The single peaks were analyzed by
HPLCandmassspectrometry.AnalyticalRP-HPLCrunswerecarried
out on a HP Agilent Series 1100 apparatus (Santa Clara, CA, USA)
usingaPhenomenex (Torrance,CA)C18column,4.6mm×250 mm
withaflowrateof1.0 mlmin−1. For all theRP-HPLCprocedures, the
system solvent used was H2O 0.1% TFA (A) and CH3CN 0.1% TFA
(B), with a linear gradient from from 5 to 70% B in 30 min followed
by70 to95%B in10 min.Mass spectral analysiswere carriedouton
MALDI-TOFVoyager-DEmass spectrometer Perseptive Biosystems
(Framigham, MA, USA). The desired compounds (∼180 mg) were
obtained at HPLC purity higher than 95% with a final yield of
around 10%.
(C18)2-(AhOH)-Lys(DTPAGlu)-(AhOH)2-octreotide,
OCA-DTPAGlu, Rt = 41.0 min;MW = 3204 amu.
(C18)2-(AhOH)-Lys(DOTA)-(AhOH)2-octreotide,
OCA-DOTA, Rt = 41.3 min;MW = 3144 amu.
Preparation of Gadolinium Complexes
Gadolinium complexes have beenobtainedby adding light excess
of the GdCl3 to aqueous solution of OCA-DTPAGlu andOCA-DOTA
ligands at neutral pH and room temperature. The formation of
the gadolinium complexeswas followedbymeasuring the solvent
proton relaxation rate (1/T1). The excess of uncomplexed Gd(III)
ions, which yields a variation of the observed relaxation rate,
was removed by centrifugation of the solution brought to pH 10;
further relaxation rate measurements were made to check the
complete Gd(III) ions removal.
Preparation of Micelle Containing Solutions
Stock solutions of OCA-DTPAGlu and OCA-DOTA monomers and
of their gadolinium complexes were prepared by stirring the
monomers until complete dissolution in 0.1 M phosphate buffer at
pH 7.4 and filtering through a 0.45 µm filter. Concentrations
of all solutions (1.0 × 10−3 M for OCA-DTPAGlu, OCA-DOTA
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Micelles derivatized with octreotide
and OCA-DTPAGlu(Gd); and 1.0 × 10−4 M for OCA-DOTA(Gd))
were determined by absorbance on a UV–vis Jasco V-5505
spectrophotometer (Easton, MD, USA) equipped with a Jasco ETC-
505T Peltier temperature controller with a 1-cm quartz cuvette
using a molar absorptivity (ε280) of 5630 M−1 cm−1 for octreotide,
due to the contribution of tryptophan residue present in the
primary octreotide structure [38,39].
Fluorescence Measurements
Emission spectra were recorded using a Jasco Model FP-750
spectrofluorimeter equippedwith a Peltier temperature controller
in 1.0-cm path length quartz cell at 25 ◦C. Equal excitation and
emission bandwidths were used throughout experiments, with
a recording speed of 125 nm min−1 and automatic selection
of the time constant. The cmc values were obtained by using
8-anilinonaphthalene-1-sulfonate (ANS) as a fluorescent probe.
Small aliquots of 1 × 10−4 M aggregates solution, were added
to a fixed volume of fluorophore in the cell (1 × 10−5 M ANS)
dissolved in the same buffer. The cmc values were determined by
linear least-squares fitting of the fluorescence emission at 480 nm,
upon excitation at 350 nm versus the amphiphile concentration as
previously reported [26,40].
Tryptophan emission spectra in 290–450 nm range were
obtained exciting at 280 nm micelle solutions at monomer
concentration of 1.0 × 10−5 M for OCA-DTPAGlu and OCA-DOTA;
and 1.0 × 10−4 M for OCA-DTPAGlu(Gd) and OCA-DOTA(Gd).
Circular Dichroism (CD) Experiments
Far-UV CD spectra were collected at room temperature on a Jasco
J-810 spectropolarimeter equippedwith aNesLab RTE111 thermal
controller unity using a 1-mm quartz cell. Other experimental
settings were: scan speed, 10 nm/min; sensitivity, 50 mdeg;
time constant, 16 s; bandwidth, 3 nm. CD measurements were
conductedon solutions containingpeptide amphiphilic surfactant
at concentrationsof 1×10−4 M, 1×10−5 Mand1×10−6 M in2.5 mM
phosphate buffer at pH 7.4. The CD spectra were collected from
260 to 190 nm, corrected for blank and adjusted for dilution.
Water Proton Relaxation Measurements
The longitudinal water proton relaxation rates were measured on
a Stelar Spinmaster (Mede, Pavia, Italy) spectrometer operating at
20 MHz, by means of the standard inversion-recovery technique
(16 experiments, 2 scans). A typical 90◦ pulse width was 4 µs and
the reproducibility of the T1 data was ±0.5%. The temperature
was maintained at 298 K with a Stelar VTC-91 air-flow heater
equipped with a copper-constantan thermocouple (uncertainty
±0.1 ◦C). The proton 1/T1 NMRD profiles were measured over
a continuum of magnetic field strength from 0.00024 to 0.28 T
(corresponding to 0.01–20 MHz proton Larmor Frequency) on a
Stelar fast field-cycling relaxometer. This relaxometer works under
complete computer control with an absolute uncertainty in 1/T1
of ±1%. Data points from 0.47 T (20 MHz) to 1.7 T (70 MHz) were
collected on a Stelar Spinmaster spectrometer working at variable
field.
Biological Assays
Radiolabeling of OCA-DTPAGlu aggregates was performed at
monomer concentrationof 1.0×10−3 M. Trace amounts of 111InCl3
and up to 500 µCi were added to the aggregate formulation after
addition of an equal volume of 0.5 N sodium citrate. Confirmation
of incorporation of the label into the aggregates was obtained by
gel filtration on Sephadex G-50 prepacked columns (Pharmacia
Biotech). Binding activity was tested on A431 cells overexpressing
the SSTR2 by stable transfection and compared to control cells.
Assays were performed at 37 ◦C on cell suspensions that were
incubated with the radiolabel aggregates for 1 h. Concentration
of the monomers in the cell binding assays were always kept
above 10−4 M. Radioactivity bound to cells was separated from
unbound activity by centrifugation through dibutyl phthalate in
1.5 ml tubes which were subsequently frozen on dry ice, the cell
pellet containing portion of the tube excised and counted in a
Wallac gamma counter. Unbound radioactivity was placed in a
separate vial and counted as well.
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